Blueprint Medicines Receives a Buy from BTIG


In a report issued on June 15, Dane Leone from BTIG maintained a Buy rating on Blueprint Medicines (NASDAQ: BPMC), with a price target of $107. The company’s shares opened today at $69.44.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 20.8% and a 71.8% success rate. Leone covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics Inc, Vertex Pharmaceuticals, and G1 Therapeutics Inc.

Currently, the analyst consensus on Blueprint Medicines is Strong Buy and the average price target is $105.25, representing a 51.6% upside.

In a report issued on June 4, JMP Securities also maintained a Buy rating on the stock with a $103 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $109 and a one-year low of $39.99. Currently, Blueprint Medicines has an average volume of 507.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Blueprint Medicines Corp. engages in the research, development, and commercialization of pharmaceutical products. It focuses on medicines to improve the lives of patients with genomically defined cancers and rare diseases. Its portfolio includes BLU-285 and BLU-554 for the treatment of gastrointestinal stromal tumors, systemic mastocytosis, and leukemia.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts